The primary endpoint in AleNephro was met , indicating that in stage @ chronic kidney disease patients with type @ diabetes , the decrease in estimated glomerular filtration rate after @ weeks ' treatment with aleglitazar followed by @ weeks off-treatment was reversible and comparable ( non-inferior ) to pioglitazone .